The kinetics of inhibition of tissue-type plasminogen activator (t-PA) by the fast-acting plasminogen activator inhibitor-I (PAI-1) was investigated in homogeneous (plasma) and heterogeneous (solid-phase fibrin) systems by using radioisotopic and spectrophotometric analysis. It is demonstrated that fibrinbound t-PA is protected from inhibition by PAI-1, whereas t-PA in soluble phase is rapidly inhibited (K1 = I07 M-1 s-1) even in the presence of 2,uM-plasminogen. The inhibitor interferes with the binding of t-PA to fibrin in a competitive manner. As a consequence the Kd of t-PA for fibrin (1.2 + 0.4 nM) increases and the maximal velocity of plasminogen activation by fibrin-bound t-PA is not modified. From the plot of the apparent Kd versus the concentration of PAI-I a K1 value of 1.3 + 0.3 nm was calculated. The quasi-similar values for the dissociation constants between fibrin and t-PA (Kd) and between PAI-I and t-PA (K1), as well as the competitive type of inhibition observed, indicate that the fibrinolytic activity of human plasma may be the result of an equilibrium distribution of t-PA between both the amount of fibrin generated and the concentration of circulating inhibitor.
INTRODUCTION
The endothelial tissue-type plasminogen activator (t-PA, EC 3.4.21.-) present in plasma is the serine proteinase responsible for physiological fibrinolysis (Astrup, 1956; Miillertz, 1987) . The activity of this activator is highly stimulated by fibrin (Thorsen et al., 1972) and specifically inhibited by PA inhibitors (Sprengers & Kluft, 1987) . The fast-acting inhibitor of endothelial-cell origin (Dosne et al., 1978; Loskutoff et al., 1983) present in plasma Kruithof et al., 1984; Wiman et al., 1984; Verheijen et al., 1984) , PAI-1, reacts with both single-chain t-PA (sc-t-PA) and two-chain t-PA (tc-t-PA) and with the twochain urinary-type plasminogen activator EC 3.4.21.31 ) with a second-order rate constant of above 107m-l s-W. PAI-i forms SDS-stable complexes with these activators (Levin, 1983; Philips et al., 1984) . The inhibitor of placental origin (Kawano et al., 1968; Astedt et al., 1985) , PAI-2, also found in plasma during pregnancy (Lecander et al., 1984) , can inhibit tc-t-PA and tc-u-PA with a second-order rate constant of 106 M-1 s-'. A recently described PA inhibitor of urinary origin (Stump et al., 1986) , PAI-3, is immunologically identical (Heeb et al., 1987) with the inhibitor of activated protein C (Suzuki et al., 1983) and reacts specifically with tc-u-PA with a second-order constant of above 8 x I03 m-1 s-'. Non-specific inhibition of plasminogen activators by other serine proteinase inhibitors (a2-antiplasmin, a2-macroglobulin) has been described in purified systems (Korninger & Collen, 1981 ; but probably plays no role in a plasma milieu. Therefore, because of its plasma concentration (about 1.3 nM) and its second-order rate constant for the inhibition of t-PA, it is generally accepted that in physiological conditions only PAI-I (and PAI-2 during pregnancy) could play a significant role in fibrinolysis. Indeed, most of the t-PA in plasma circulates complexed to PAI-I Booth et al., 1985) , and a correlation has been reported between high concentrations of PAI-I and thromboembolic diseases (Juhan-Vague et al., 1987) . However, its relevance in the regulation of physiological fibrinolysis is still a matter of debate (Sprengers & Kluft, 1987) . Liquid-phase methods based on the measurement of residual t-PA activity have been developed (Verheijen et al., 1984; Wiman et al., 1984) to study this problem. Although useful, they are subject to several drawbacks: the use of fibrin substitutes instead of fibrin, the presence of sc-u-PA and a2-antiplasmin in plasma, and the particular conditions inherent to this type of assays, e.g. dilution or acidification of plasma, which can modify the equilibrium of t-PA-PAI-I complexes. The aim of the present work was to investigate the interaction between PAI-I and t-PA under conditions where the experimental complications mentioned above can be avoided. Our method employs a solid-phase fibrin network close to the physiological model and a spectrophotometric system that allows the study of t-PA-inhibition kinetics either in a purified system or in a plasma milieu.
MATERIALS AND METHODS Chemicals and reagents
All the chemicals used were reagent grade and were obtained from either Prolabo (Paris, France) or Aldrich (Beerse, Belgium). Other products were obtained as indicated: EDTA, bovine serum albumin, Triton X-100 and Tween 20 were from Serva (Heidelberg, Germany); Vol. 256 Abbreviations used: Pg, plasminogen; Fn, fibrin; PA, plasminogen activator; t-PA, tissue-type PA; sc-t-PA, single-chain t-PA; tc-t-PA, two-chain t-PA; u-PA, urinary-type PA; sc-u-PA, single-chain u-PA; PAI-1, PA inhibitor-1. The last seven are in accordance with the recommendations of the Subcommittee on Fibrinolysis of the International Society of Hemostasis and Thrombosis (1986).
* To whom correspondence should be addressed. the bovine serum albumin used was proven to be free of plasmin and t-PA enzymic and inhibitory activities; glutaraldehyde in aqueous 250 (v/v) solution was from TAAB Laboratories (Reading, Berks., U.K.); poly(vinyl chloride) U-shaped micro-titration plates and plate sealers were from Dynatech France (Marnes-LaCoquette, France); Ultrogel AcA 44 and DEAE-Trisacryl were from IBF (Villeneuve-la-Garenne, France); lysine-Sepharose 4B and gelatin-Sepharose 4B were from Pharmacia Fine Chemicals (Uppsala, Sweden); chromogenic substrates D-norleucylcyclohexylalanylarginine pnitroanilide (CBS 3308) and methylmalonylhydroxyprolylarginine p-nitroanilide (CBS 1065) were from Diagnostica Stago (Asnieres, France); aprotinin (Trasylol) was from Bayer (Leverkusen, Germany); bovine thrombin was from Hoffmann-LaRoche (Basel, Switzerland); low-Mr markers were from Bio-Rad Laboratories (Richmond, CA, U.S.A.). Plasma and PAI-depleted plasma Human blood was collected from healthy volunteers (students and staffmembers, ages 20 to 40 years). Samples were drawn into a polypropylene tube containing 0.013 M-sodium citrate final concentration, kept on ice, and centrifuged immediately at 2000 g for 15 min at 4°C to obtain platelet-poor plasma. A pool of plasma samples was prepared and a fraction was made deficient in PAI-I by immunoadsorption of t-PA-PAI-1 complexes on an anti-t-PA monoclonal antibody-Sepharose 4 B column after addition of an excess of melanoma t-PA (200 i.u./ ml, final concentration) to plasminogen-depleted plasma. Plasma thus prepared had a normal concentration of c2-antiplasmin (Teger-Nilsson et al., 1977) . The basal concentration of free t-PA in the pooled plasma was tested as indicated elsewhere (Angles-Cano, 1986 ). The content of PA inhibitor activity (20 units/ml) and its depletion from plasma were determined as described below under 'Assay procedures for the inhibition of t-PA '. Purified proteins Glul-plasminogen was purified from di-isopropyl phosphorofluoridate-treated fresh-frozen human plasma by affinity chromatography on lysine-Sepharose 4B (Deutsch & Mertz, 1970) , ion-exchange chromatography on DEAE-Trisacryl and gel filtration on Ultrogel AcA 44 in the presence of Trasylol. The concentration of Glul-plasminogen was determined spectrophotometrically by using A1`m28O = 16.8 (Wallen & Wiman, 1972) , and 20 /M stock solutions in buffer A were stored at -80 'C. Fibrinogen was purified from human plasma by glycine precipitation at room temperature as previously described (Kazal et al., 1963) , and chromatographed successively on lysine-Sepharose 4B (Deutsch & Mertz, 1970) and gelatin-Sepharose 4B (Engvall & Ruoslahti, 1977) to remove plasminogen and fibronectin respectively. Fibrinogen concentration was determined spectrophotometrically by using A" =m280 15.1 (Blomback & Blomback, 1956) , and fractions containing 12 mg/ml in buffer A were stored at -80 'C. Tissue plasminogen activator (> 95 % single-chain t-PA) was purified from the conditioned medium of human Bowesmelanoma-cell cultures as previously described (Rijken & Collen, 1981) 
Endothelial-cell cultures
The human vascular endothelial cells employed for the purification of the inhibitor were isolated from umbilical cord veins (Jaffe et al., 1973) and cultured in minimal essential medium type alpha containing 150 (v/v) foetal-calf serum (Rehatuin; Armour Biochemical Co., Kankakee, IL, U.S.A.), 20,g of endothelial-cell growth factor (Collaborative Research, Lexington, MA, U.S.A.)/ml and 90,g of heparin (Organon, Teknika, Fresnes, France)/ml as described previously (Thornton et al., 1983) . The culture medium thus prepared was determined to be free of PAI-I inhibitory activity. Conditioned medium was collected at confluency, pooled, centrifuged at 2000 g for 5 min to remove cell debris, determined to be rich in PAI-I by reverse fibrin autography (Loskutoff et al., 1983 ) and stored at -70°C until further use. Endothelial-cell cultures were obtained through the kind collaboration of Dr. L. Coulombel (H6pital de Bicetre). Partial purification of PAI-1
The semi-purified inhibitor was obtained from conditioned medium by two (NH4)2SO4 fractionations and DEAE-Trisacryl chromatography, as follows. Solid (NH4)2S04 was added to 7000 saturation and stirred twice for 30 min, first at 22°C and then at 4 'C. After centrifugation at 10000 g for 30 min at 4 'C the precipitate was resuspended in and dialysed against the equilibrium buffer of the DEAE-Trisacryl column. The second (NH4)2SO4 fractionation was done at 5000 saturation under the same conditions. The final solution was passed through a DEAE-Trisacryl column (2.5 cm x 30 cm) pre-equilibrated with 0.025 M-sodium phosphate buffer, pH 6.5, containing 0.035 M-NaCl. Proteins in the flow-through were discarded and the retained PAI-i was eluted by using a linear gradient of 0.035-0.5 M-NaCl in the same buffer. Fractions containing the t-PA-inhibitory activity (detected as indicated below) were pooled, concentrated in a dialysis bag against poly(ethylene glycol) (Mr 20000) , dialysed against sodium phosphate buffer and stored at -70 'C until used. All procedures were performed at 4 'C.
Buffers
Buffer A was 0.05 M-sodium phoshate buffer, pH 7.4, containing 0.08 M-NaCl. Buffer B was 0.05 M-sodium phosphate buffer, pH 6.8, containing 0.08 M-NaCl. Assay buffer was buffer A containing 2 mg of bovine serum albumin/ml and 0.050 Tween 20. Binding buffer was buffer B containing 4 mg of bovine serum albumin/ ml, 0.010% Tween 20 and 2 mM-EDTA. All other buffers were prepared as described in the text. Preparation of solid-phase fibrin supports
The solid-phase fibrin supports for the specific assessment of t-PA activity were prepared as described previously (Angles-Cano, 1986) . Briefly, poly(vinyl chloride)-bound stable polyglutaraldehyde derivatives were first produced by treating poly(vinyl chloride) plates with 2.5% (v/v) glutaraldehyde in 0.1 M-sodium bicarbonate buffer, pH 9.5, for 2 h at 22 'C. Then fibrinogen (0.3 gM in 0.1 M-sodium phosphate buffer, pH 7.4, containing 1 mM-CaC12) was covalently bound for 18 h at 4 'C. The excess fibrinogen was discarded, the plate was washed with assay buffer and a fibrin network was generated by thrombin treatment (1 N.I.H. unit/ml in assay buffer containing 1 mM-CaC12). The excess thrombin was discarded and fibrin-bound thrombin was eluted by three washes with a high-ionic-strength solution (0.5 M-NaCl/8 mM-CaCl2/0.05 00 Tween 20). A final wash with 5 mM-sodium phosphate buffer, pH 6.8, containing 0.0500 Tween 20 was done, and 100l1 of buffer B containing 0.02 M-L-lysine, 0.2% bovine serum albumin and 0.01 % NaN3 was added. The plate was sealed and stored in this state at 4 'C until further use. Assay procedures for the inhibition of t-PA The t-PA-inhibitory capacity of plasma and purified PAI-I was investigated by using two different inhibition approaches and was quantified by measuring the amount of residual fibrin-bound t-PA, as follows.
Inhibition of fibrin-bound t-PA. Solutions of melanoma t-PA containing 5 and 10 i.u./ml were preparated in binding buffer, and amounts of 100 lO per well were incubated in a solid-phase fibrin plate for 1 h at 37 'C. The wells were then washed with binding buffer, and amounts per well of 100 ,1 of binding buffer, plasma or PAI-depleted plasma, supplemented with 0-40 units of purified PAI-I /ml, were incubated at 37 'C on the fibrinbound t-PA for 0-120 min. Unbound proteins were eliminated by extensive washing with binding buffer, and bound t-PA was determined by using the spectrophotometric method described below.
Inhibition of t-PA in solution. Solutions of binding buffer containing 100-10 000 units of melanoma t-PA/ml were diluted (1:10, v/v) with binding buffer, plasma or PAI-depleted plasma supplemented with 0-100 units of purified PAI-1/ml. After 15 min incubation at room temperature 100 1ul of each mixture per well was incubated in a solid-phase fibrin plate for 1 h at 37 'C. The plate was then extensively washed with binding buffer, and the residual t-PA activity was determined spectrophotometrically as described below. Determination of the activity of fibrin-bound t-PA The amount of t-PA quenched by the inhibitor was indirectly determined by measuring the activity of residual t-PA bound to fibrin as previously described (Angles-Cano, 1986 Initial rates for each kinetic were calculated by using an appropriate statistical analysis of data in its original co-ordinate system, i.e. AA405 versus t. Since the progress curve thus obtained is described by a parabolic relationship (Kosow, 1975; Christensen & Miillertz, 1977; Petersen et al., 1985) and the acceleration of the reaction is proportional to the activation of plasminogen, the initial rates were calculated by determining the equation ofsecond degree for linear motion with constant acceleration, X = 2at2 + bt + c, as follows. The progress curve was represented by 50 experimental measurements evenly distributed in the initial parabolic period of the trace, where the acceleration of product formation is constant. To obtain the slope that corresponds better to the experimental points, the data were fitted to five polynomials (orders 1 and 3 to 6) by using non-linear leastsquares analysis. The variance of each fit with respect to the experimental points minimized by the degree of the polynomial was calculated and the one with the least estimated standard deviation was taken to express the initial velocity from the slope of its maximal tangent.
This was proportional to the concentration of [t-PA]Fn in the interval corresponding to the initial phase of the fibrin binding curve. This approach was used to avoid errors inherent to a graphical transformation of the parabolic curve into straight lines. It requires computer treatment, which is included in a program of the package used for the monitoring of the assay and the collection of the data. Plasminogen-t-PA-PAI-1 interaction in the absence of fibrin Reactions were performed in a fibrin-free system with poly(vinyl chloride) U-shaped micro-titration plates and a plasmin substrate (CBS 1065) with a high catalyticcentre activity. Mixtures containing (final concentrations) purified t-PA (10 i.u./ml) and PAI-1 (2.5-40 units/ ml) were equilibrated at room temperature for 15 min or were immediately mixed with plasminogen (50 nM-2 #M).
The rates of activation in the presence and in the absence of PAI-I were determined with 1.5 mM-CBS 1065 in a final volume of 501,. Absorbance readings and initial velocities were determined in triplicate as indicated before. Formation of complex between semi-purified PAI-1 with t-PA To monitor the formation of complexes, radiolabelled t-PA (3 #tCi/ml) and PAI-1 (0-320 units/ml) were mixed Vol. 256
Miscellaneous
The human melanoma t-PA was used as the internal standard. Its activity was expressed in i.u. by reference to the First International Standard for t-PA (preparation 83/517). The basal concentration of free t-PA in the pooled plasma was tested as indicated above and was less than 0.01 i.u./ml. Protein was determined by using the method of Bradford (1976) . Melanoma t-PA (Biopool) was radioiodinated by the Iodogen method (Fraker & Speck, 1978) with a labelling time of 4 min at 4°C; the specific radioactivity obtained was 40 nCi/ng and the specific activity was 0.7 i.u./ng.
RESULTS AND DISCUSSION Characteristics of the PAI-enriched fraction
A semi-purified fraction with a high content of PAI activity (3000 units/ml) was obtained from endothelialcell culture supernatants. Although several protein bands were observed by SDS/polyacrylamide-gel electrophoresis, a main band in the 54000-Mr zone was present and identified as PA inhibitor by reverse fibrin autography (Loskutoffet al., 1983) . The semi-purified product was immunologically related to PAI-I by using specific monoclonal antibodies and was able to form a complex of Mr 110000 with sc-t-PA. The PAI-I activity of this preparation was decreased by prolonged incubation at 37°C but was not modified by treatment with denaturants (results not shown). The PAI-I-enriched fraction contained 5 mg of protein/ml, and from this a specific activity of 600 units/mg was calculated. A 40-fold purification was thus obtained by reference to the initial source. Inhibition of fibrin-bound t-PA No significant inhibition of fibrin-bound t-PA by its fast-acting inhibitor present in plasma or in the semipurified source could be demonstrated. As shown in Fig.  1 , the results obtained with different t-PA/fibrin molar ratios and different incubation times were similar for both plasma and buffer. In the semi-purified system prolonged incubation periods (over 60 min) or a very low t-PA/PAI-1 ratio were necessary to observe a decrease in t-PA activity. This was correlated with a similar decrease in the amount of bound radiolabelled t-PA (results not shown). The In contrast with the solid-phase t-PA-inhibition experiments, t-PA in solution was efficiently quenched by PAT-1 present in plasma or in the semi-purified source. The curves shown in Fig. 2(a) of t-PA to fibrin in the absence and in the presence of PAI-1. They were obtained by plotting the initial velocity of residual fibrin-bound t-PA versus the initial t-PA concentration input. The t-PA-binding curve obtained with buffer is identical with the one obtained with PAIdepleted plasma. This indicates that the main factor able to modify the binding of t-PA to fibrin is the presence of PAI-I through the formation of t-PA-PAI-I complexes, which were identified by SDS/polyacrylamide-gel electrophoresis and autoradiography (Fig. 3) . As a consequence, in the presence of PAI-1, e.g. normal plasma, the binding curve is shifted to the right, producing three different zones (Straus & Goldstein, 1943 ) of t-PA activity, which correspond to the presence of free and/or complexed t-PA as determined by SDS/polyacrylamide-gel electrophoresis and autoradiography (Fig. 2b) . These experimentally observed zones can be represented by the inhibition equation governing the t-PA-PAI-1 interaction under equilibrium conditions (see below). Zone A corresponds to the quenching of small amounts of t-PA by a relative excess of PAI-1. Therefore the amount of free t-PA can be neglected and no or very low residual t-PA activity can be detected. In zone B three forms of t-PA can be distinguished: free, complexed to PAI-I and bound to fibrin. The last is the molecular form detected by our assay. This zone corresponds to a region around the half-saturation boundary of the binding curve. In zone C the amount of t-PA exceeds PAI-I and upon saturation of fibrin the binding asymptote approaches the one obtained in the absence of PAI-1. Determination of the dissociation constant (Kd) of the t-PA-Fn interaction in the presence of PAI-1
Under the conditions described, the semi-logarithmic transformation of the binding isotherm (Fig. 2a inset (inflexion point). 
In this scheme, both Fn and Pg interact with t-PA, making the activation process analogous to a twosubstrate enzyme system. It has been shown (Hoylaerts et al., 1982) that the activation follows a sequential mechanism. The formation of a Fn-t-PA complex:
is the preliminary step that induces a modification of the quaternary structure of t-PA and enhances the binding and cleavage of native Pg: kt-n+2 [Pg
The affinity of the t-PA-Fn interaction (eqn. 2) is defined by:
and the velocity (v) of Pg breakdown by:
If both substrates are present in excess the reaction will follow zero-order kinetics and virtually all the t-PA will form a ternary complex with Fn and Pg, so:
In the presence of t-PA inhibitor, e.g. PAI-1, a fraction of [t-PA]o will combine with it to form inactive complexes:
where the inhibition constant is given by:
Vol. 256 The formation of such complexes will modify the initial rate, by interfering with the activity of t-PA at the level where each substrate participates in the reaction sequence. Since in the absence of Fn the K. of Pg for t-PA (62 /LM) is at least 30-fold higher than its plasma concentration (approx. 2 uM) the rate of plasminogen activation will be very low even in the absence of PAI-1. This is indeed the case, as indicated in Fig. 4 . As shown, high concentrations of Pg were unable to modify the t-PA-PAI-1 interaction. Therefore PAI-I cannot be considered to be an inhibitor of t-PA at the Pg-t-PA interaction level in the absence of Fn. However, if we consider that Fn behaves in a substrate-like manner in the reaction sequence of activation, then the possibility that PAI-I could be a modulator of the t-PA-Fn interaction should be considered. In such a case, the residual t-PA, i.e. [t-PA]R in eqn. (7), will be a function of the inhibition constant (eqn. 8) and of the affinity of t-PA for Fn (eqn. 4), and can be represented by: (10) and the fractional activity, a, which is the relation between v in the presence of inhibitor and V in its absence, by:
By substitution from eqns. (5), (6) and (9) (Fig. 2a) it is clear that the best zone for the calculation ofthe fractional inhibition is zone B. This zone corresponds to a state of equilibrium determined by the affinity constant of both the t-PA-Fn (eqn. 4) and the t-PA-PAI-1 (eqn. 8) interactions. This is in agreement with our previously published data and with results shown in Fig. 5 (128(14): Determination of the inhibition constant (K1) of PAI-1 for t-PA The plot of initial velocities (v) versus t-PA concentrations (Fig. 2a) , represented by an hyperbola, can be conveniently transformed into a straight line by using a double-reciprocal plot of data (Fig. 5) . The intercept on the abscissa axis corresponds to -1 /Kd or -I/Kd if PAI-I is present in the reaction mixture. For different concentrations of PAI-I present in plasma or in buffer the curves of the double-reciprocal plot intercept at the same value of y, indicating an identical V and thus a competitive type of inhibition by PAI-1. Since the Kd obtained are a linear function of the inhibitor concentration, a plot of K, versus PAI-I concentrations (Fig. 5 inset) provides the t-PA-PAI-I dissociation constant, K1, at -I/Ki. This value of K1 was obtained in units/ml, but, as a stoichiometric association is assumed between t-PA and PAI-1, the molarity can be obtained by using the specific activity of t-PA and the Mr of the inhibitor. Thus a value of 1.3+0.3 nm was determined for both plasma and semi-purified PAI-1.
CONCLUSION
We report here the results of a study on the inhibition of t-PA by its fast-acting inhibitor, PAI-1, present in plasma and secreted by endothelial cells. Whereas in other studies a method in liquid phase with fibrin substitutes or CNBr-cleavage fragments of fibrinogen has been employed to measure residual t-PA activity, our approach was to study t-PA inhibition under conditions as close as possible to the physiological situation, i.e. with fibrin in solid phase. An interesting advantage of this approach is that our method physically removes the many variable components of biological samples that may influence activator activity. Thus both the inhibition of t-PA by PAI-i and the activation of plasminogen by residual t-PA can be conveniently analysed. The doublereciprocal plot (Fig. 5) of the inhibition data revealed that PAI-I behaves as a competitive inhibitor of the binding of t-PA to fibrin. Since the inhibition constant (K1) of PAI-I for t-PA is of the same order of magnitude (1.3 + 0.3 nM) as the dissociation constant of the t-PA-Fn interaction (1.2 + 0.4 nM), the formation of t-PA-PAI-I complexes resulting in impaired fibrinolysis or of Fnt-PA complexes leading to the lysis of clots will be a function of the relative concentrations of PAI-I and fibrin. Thus, in an early stage, t-PA-PAI-1 complexes will be able to dissociate in the presence of a thrombus equivalent to a massive amount of fibrin. That this is probably the case is strongly supported by our experiments showing that PAI-I is an inefficient inhibitor of fibrin-bound t-PA in spite of the active site being exposed. In other words, no binding of PAI-I to the Fn-t-PA complex and therefore no modification of the kinetics of the activation were observed. This is probably due to steric hindrance of the PAI-I-binding site and suggests that it involves a sequence in or close to the fibrinbinding domain of t-PA. An analogous protective effect has been described for the inhibition of fibrin-bound plasmin by a2-antiplasmin (Wiman & Collen, 1978) . In parallel experiments we have shown (Fig. 4) that plasminogen at plasma concentration does not modify the equilibrium of the t-PA-PAI-I interaction in the absence of fibrin, i.e. plasminogen does not displace the inhibitor from the t-PA-PAI-1 complexes. Moreover, since the activation of plasminogen by t-PA in the absence of fibrin is an unproductive process, we cannot consider PAI-I to be an inhibitor of the activation at this level. The interference of PAI-I with the activation of plasminogen will be therefore localized at the fibrin surface by interfering with the binding of t-PA.
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